Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China.
BMC Cancer. 2021 Mar 16;21(1):280. doi: 10.1186/s12885-021-07938-x.
Although criteria for liver transplantation, such as the Milan criteria and Hangzhou experiences, have become popular, criteria to guide adjuvant therapy for patients with hepatocellular carcinoma after liver transplantation are lacking.
We collected data from all consecutive patients from 2012 to 2019 at three liver transplantation centers in China retrospectively. Univariate and multivariate analyses were used to analyze preoperative parameters, such as demographic and clinical data. Using data obtained in our center, calibration curves and the concordance Harrell's C-indices were used to establish the final model. The validation cohort comprised the patients from the other centers.
Data from 233 patients were used to construct the nomogram. The validation cohort comprised 36 patients. Independent predictors of overall survival (OS) were identified as HbeAg positive (P = 0.044), blood-type compatibility unmatched (P = 0.034), liver transplantation criteria (P = 0.003), and high MELD score (P = 0.037). For the validation cohort, to predict OS, the C-index of the nomogram was 0.874. Based on the model, patients could be assigned into low-risk (≥ 50%), intermediate-risk (30-50%), and high-risk (≤ 30%) groups to guide adjuvant therapy after surgery and to facilitate personalized management.
The OS in patients with hepatocellular carcinoma after liver transplantation could be accurately predicted using the developed nomogram.
尽管米兰标准和杭州经验等肝移植标准已经流行,但缺乏指导肝癌患者肝移植后辅助治疗的标准。
我们回顾性地从中国的三个肝移植中心收集了 2012 年至 2019 年所有连续患者的数据。使用单变量和多变量分析来分析术前参数,如人口统计学和临床数据。使用我们中心获得的数据,绘制校准曲线和一致性哈雷尔 C 指数,以建立最终模型。验证队列包括来自其他中心的患者。
使用 233 名患者的数据构建了列线图。验证队列包括 36 名患者。总生存(OS)的独立预测因素包括 HbeAg 阳性(P=0.044)、血型不匹配(P=0.034)、肝移植标准(P=0.003)和高 MELD 评分(P=0.037)。对于验证队列,列线图的 C 指数为 0.874,可用于预测 OS。根据该模型,患者可以被分为低风险(≥50%)、中风险(30-50%)和高风险(≤30%)组,以指导术后辅助治疗,并促进个性化管理。
使用开发的列线图可以准确预测肝癌患者肝移植后的 OS。